Limits...
Antipsychotic treatments; focus on lurasidone.

Sumiyoshi T - Front Pharmacol (2013)

Bottom Line: However, these views have been partly challenged by results from recent meta-analysis studies.Specifically, cardio-metabolic side effects of AAPDs, in spite of a relative paucity of extrapyramidal symptoms, may sometimes limit the use of these agents.Further investigations are warranted to determine if a larger proportion of patients will be benefitted by treatment with AAPDs compared to TAPDs in terms of remission and recovery.

View Article: PubMed Central - PubMed

Affiliation: Neurocognition and Pharmacology Laboratory, Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences Toyama, Japan.

ABSTRACT
The introduction of atypical antipsychotic drugs (AAPDs), or second-generation antipsychotics, with clozapine as the prototype, has largely changed the clinicians' attitudes toward the treatment of mental illnesses including, but not limited to schizophrenia. Initially, there was optimism that AAPDs would be superior over typical antipsychotic drugs (TAPDs), or first-generation antipsychotic drugs, in terms of efficacy in various phenomenological aspects, including cognitive impairment, and less likelihood of causing adverse events. However, these views have been partly challenged by results from recent meta-analysis studies. Specifically, cardio-metabolic side effects of AAPDs, in spite of a relative paucity of extrapyramidal symptoms, may sometimes limit the use of these agents. Accordingly, attempts have been made to develop newer compounds, e.g., lurasidone, with the aim of increasing efficacy and tolerability. Further investigations are warranted to determine if a larger proportion of patients will be benefitted by treatment with AAPDs compared to TAPDs in terms of remission and recovery.

No MeSH data available.


Related in: MedlinePlus

UCSD Performance-based Skills Assessment—Brief version (UPSA-B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3753015&req=5

Figure 8: UCSD Performance-based Skills Assessment—Brief version (UPSA-B).

Mentions: In the acute study patients were randomized to receive treatment with lurasidone 80 mg (N = 125), 160 mg (N = 121), quetiapine 600 mg (N = 120), or placebo (N = 122). Subjects who completed the 6-week treatment were eligible for the double-blind extension study to receive a once-daily flexible dose of lurasidone (40–160 mg/day; N = 151) or quetiapine (200–800 mg/day; N = 85). Subjects who received placebo in the acute study were administered lurasidone (40–160 mg/day; N = 56). Cognitive performance was examined with the computerized CogState battery (Pietrzak et al., 2009) at baseline of the acute phase, and after 6, 19, and 32 weeks of treatment. The battery consists of eight tasks that measure verbal learning, speed of processing, attention/vigilance, visual working memory, visual memory, spatial working memory, reasoning and problem solving, and social cognition (Pietrzak et al., 2009). The average of standardized Z-scores from each task was used as the valid neurocognitive composite Z-score. Functional capacity was evaluated with UCSD Performance-based Skills Assessment—Brief version (UPSA-B) (Mausbach et al., 2011) (Figure 8).


Antipsychotic treatments; focus on lurasidone.

Sumiyoshi T - Front Pharmacol (2013)

UCSD Performance-based Skills Assessment—Brief version (UPSA-B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3753015&req=5

Figure 8: UCSD Performance-based Skills Assessment—Brief version (UPSA-B).
Mentions: In the acute study patients were randomized to receive treatment with lurasidone 80 mg (N = 125), 160 mg (N = 121), quetiapine 600 mg (N = 120), or placebo (N = 122). Subjects who completed the 6-week treatment were eligible for the double-blind extension study to receive a once-daily flexible dose of lurasidone (40–160 mg/day; N = 151) or quetiapine (200–800 mg/day; N = 85). Subjects who received placebo in the acute study were administered lurasidone (40–160 mg/day; N = 56). Cognitive performance was examined with the computerized CogState battery (Pietrzak et al., 2009) at baseline of the acute phase, and after 6, 19, and 32 weeks of treatment. The battery consists of eight tasks that measure verbal learning, speed of processing, attention/vigilance, visual working memory, visual memory, spatial working memory, reasoning and problem solving, and social cognition (Pietrzak et al., 2009). The average of standardized Z-scores from each task was used as the valid neurocognitive composite Z-score. Functional capacity was evaluated with UCSD Performance-based Skills Assessment—Brief version (UPSA-B) (Mausbach et al., 2011) (Figure 8).

Bottom Line: However, these views have been partly challenged by results from recent meta-analysis studies.Specifically, cardio-metabolic side effects of AAPDs, in spite of a relative paucity of extrapyramidal symptoms, may sometimes limit the use of these agents.Further investigations are warranted to determine if a larger proportion of patients will be benefitted by treatment with AAPDs compared to TAPDs in terms of remission and recovery.

View Article: PubMed Central - PubMed

Affiliation: Neurocognition and Pharmacology Laboratory, Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences Toyama, Japan.

ABSTRACT
The introduction of atypical antipsychotic drugs (AAPDs), or second-generation antipsychotics, with clozapine as the prototype, has largely changed the clinicians' attitudes toward the treatment of mental illnesses including, but not limited to schizophrenia. Initially, there was optimism that AAPDs would be superior over typical antipsychotic drugs (TAPDs), or first-generation antipsychotic drugs, in terms of efficacy in various phenomenological aspects, including cognitive impairment, and less likelihood of causing adverse events. However, these views have been partly challenged by results from recent meta-analysis studies. Specifically, cardio-metabolic side effects of AAPDs, in spite of a relative paucity of extrapyramidal symptoms, may sometimes limit the use of these agents. Accordingly, attempts have been made to develop newer compounds, e.g., lurasidone, with the aim of increasing efficacy and tolerability. Further investigations are warranted to determine if a larger proportion of patients will be benefitted by treatment with AAPDs compared to TAPDs in terms of remission and recovery.

No MeSH data available.


Related in: MedlinePlus